Related references
Note: Only part of the references are listed.Biosimilars in rheumatology: the wind of change
Christian K. Schneider
ANNALS OF THE RHEUMATIC DISEASES (2013)
Pharmacovigilance and biosimilars: considerations, needs and challenges
Nicole Casadevall et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
Martin H. Cohen et al.
ONCOLOGIST (2013)
The State of the Art in the Development of Biosimilars
Mark McCamish et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Comparability and biosimilarity: considerations for the healthcare provider
Jaymi F. Lee et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Steven A. Berkowitz et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Developing the Nation's Biosimilars Program
Steven Kozlowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Biosimilar drugs - Concerns and opportunities
Armando A. Genazzani et al.
BIODRUGS (2007)
Characterizing biological products and assessing comparability following manufacturing changes
AJ Chirino et al.
NATURE BIOTECHNOLOGY (2004)
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs
DJA Crommelin et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2003)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
